DELHI: Dr Reddy's Laboratories today entered into an agreement with
Hetero to distribute and market generic version of US-firm Gilead
Sciences' Hepatitis C drug under the brand 'Resof' in India.
"The company has entered into an agreement with Hetero, under which Dr
Reddy's has been licensed to distribute and market Sofosbuvir 400 mg
tablets indicated in treatment of chronic Hepatitis C under the brand
'Resof' in India," the Hyderabad-based drug major said in a BSE filing.
Labels: India, Resof (sofosbuvir)